Vertex Pharmaceuticals Is Becoming the Multi-Franchise Biotech the Market Still Refuses to Price

Summary

Vertex enters a catalyst-rich mid-2026 trading at roughly 22 times forward earnings—a discount that undervalues the company's evolving profile—despite a fortress cystic fibrosis franchise, three newer products gaining traction, and a renal pipeline asset that just cleared its pivotal clinical hurdle. The thesis is straightforward: the market still values Vertex as a single-product company, and the gap between that perception and the emerging multi-engine reality is the opportunity. I rate the stock a Buy ahead of its Q1 2026 earnings report on May 4 and the anticipated FDA decision on povetacicept in IgA nephropathy later this year.

A $12 Billion CF Engine With Built-In Margin Expansion

Vertex's cystic fibrosis franchise generated approximately $11.8 billion in 2025 net product revenue across five approved modulators. Full-year total revenue reached $12.0 billion, a 9% increase over 2024. TRIKAFTA/KAFTRIO remains the workhorse at $10.3 billion, but the more interesting story is ALYFTREK, the once-daily successor that contributed $838 million in its first partial year on market.

ALYFTREK matters more than its headline number suggests. The drug offers dosing convenience (once daily versus twice daily for TRIKAFTA), superior sweat chloride reduction, and—critically for Vertex's income statement—a lower royalty burden. Per the company's SEC filings, Vertex's position is that the royalty rate on ALYFTREK is 4%, compared with 9.33% on TRIKAFTA. As the CF installed base migrates to ALYFTREK over the next several years, Vertex's blended royalty expense should decline, providing a steady gross-margin tailwind.

On April 1, the FDA approved expanded use of both ALYFTREK and TRIKAFTA, broadening eligibility to additional age groups and genetic variants—adding roughly 800 patients in the U.S. and bringing total...